1. Altschul, R, Hoffer, A, Stephen, JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys 1955; 54: 558–559.
Google Scholar | Crossref | Medline2. Soliman, GA. Dietary cholesterol and the lack of evidence in cardiovascular disease. Nutrients 2018; 10: 780.
Google Scholar | Crossref3. Tziomalos, K, Karagiannis, A, Mikhailidis, DP, et al. Colesevelam: a new and improved bile acid sequestrant? Curr Pharm Des 2013; 19: 3115–3123.
Google Scholar4. Davidson, MH. A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. J Clin Lipidol 2011; 5: 76–81.
Google Scholar | Crossref | Medline5. Tonstad, S, Sivertsen, M, Aksnes, L, et al. Low dose colestipol in adolescents with familial hypercholesterolaemia. Arch Dis Child 1996; 74: 157–160.
Google Scholar6. Tonstad, S, Knudtzon, J, Sivertsen, M, et al. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 1996; 129: 42–49.
Google Scholar7. McCrindle, BW, O’Neill, MB, Cullen-Dean, G, et al. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. J Pediatr 1997; 130: 266–273.
Google Scholar8. Ge, L, Wang, J, Qi, W et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab 2008; 7: 508–519.
Google Scholar9. Cannon, CP, Blazing, MA, Giugliano, RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. New Engl J Med 2015; 372: 2387–2397.
Google Scholar10. Zhan, S, Tang, M, Liu, F et al. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev 2018; 11: CD012502.
Google Scholar11. Kusters, DM, Caceres, M, Coll, M, et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr 2015; 166: 1377–1384.e1.
Google Scholar12. van der Graaf, A, Cuffie-Jackson, C, Vissers, MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008; 52: 1421–1429.
Google Scholar | Crossref | Medline13. Clauss, S, Wai, KM, Kavey, RE, et al. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr 2009; 154: 869–872.
Google Scholar | Crossref | Medline14. Yeste, D, Chacón, P, Clemente, M, et al. Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. J Pediatr Endocrinol Metab 2009; 22: 487–492.
Google Scholar | Crossref | Medline15. Sunil, B, Ashraf, AP. Statin therapy in children. In: Abukabda, A, Suciu, M, Andor, M (eds) Cardiovascular risk factors in pathology. London: IntechOpen, 2020, pp. 89–111.
Google Scholar16. Wiegman, A, Hutten, BA, De Groot, E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004; 292: 331–337.
Google Scholar | Crossref | Medline17. Rodenburg, J, Vissers, MN, Wiegman, A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007; 116: 664–668.
Google Scholar | Crossref | Medline18. de Jongh, S, Lilien, MR, op’t Roodt, J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2117–2121.
Google Scholar | Crossref | Medline19. Avis, HJ, Vissers, MN, Stein, EA, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007; 27: 1803–1810.
Google Scholar | Crossref | Medline20. Vuorio, A, Kuoppala, J, Kovanen, PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2010; 7: CD006401.
Google Scholar | Crossref21. McCrindle, BW, Ose, L, Marais, AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2003; 143: 74–80.
Google Scholar | Crossref | Medline22. Stein, EA, Illingworth, DR, Kwiterovich, PO, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999; 281: 137–144.
Google Scholar | Crossref | Medline23. van der Graaf, A, Nierman, MC, Firth, JC, et al. Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia. Acta Paediatr 2006; 95: 1461–1466.
Google Scholar | Crossref | Medline24. Knipscheer, HC, Boelen, CC, Kastelein, JJ, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 1996; 39: 867–871.
Google Scholar | Crossref | Medline25. Lambert, M, Lupien, PJ, Gagné, C, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Pediatrics 1996; 97: 619–628.
Google Scholar | Medline26. Luirink, IK, Wiegman, A, Kusters, DM, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med 2019; 381: 1547–1556.
Google Scholar | Crossref | Medline27. Kusters, DM, Avis, HJ, de Groot, E, et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA 2014; 312: 1055–1057.
Google Scholar | Crossref | Medline28. Filippov, S, Pinkosky, SL, Newton, RS. LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase. Curr Opin Lipidol 2014; 25: 309–315.
Google Scholar | Crossref | Medline29. Pinkosky, SL, Newton, RS, Day, EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun 2016; 7: 13457.
Google Scholar | Crossref | Medline30. Laufs, U, Banach, M, Mancini, GJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc 2019; 8: e011662.
Google Scholar | Crossref | Medline31. Nikolic, D, Mikhailidis, DP, Davidson, MH, et al. ETC-1002: a future option for lipid disorders? Atherosclerosis 2014; 237: 705–710.
Google Scholar | Crossref | Medline32. Saeed, A, Ballantyne, CM. Bempedoic acid (ETC-1002): a current review. Cardiol Clin 2018; 36: 257–264.
Google Scholar | Crossref | Medline33. Ballantyne, CM, Davidson, MH, MacDougall, DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol 2013; 62: 1154–1162.
Google Scholar | Medline34. Ray, KK, Bays, HE, Catapano, AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019; 380: 1022–1032.
Google Scholar | Crossref | Medline35. Ballantyne, CM, Laufs, U, Ray, KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol 2020; 27: 593–603.
Google Scholar | SAGE Journals36. Nicholls, S, Lincoff, AM, Bays, HE, et al. Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J 2021; 235: 104–112.
Google Scholar | Crossref | Medline37. Feingold, KR . Cholesterol lowering drugs. In: Feingold, KR, Anawalt, B, Boyce, A, et al. (eds) Endotext. South Dartmouth, MA: MDText.com, Inc., 2000, https://www.ncbi.nlm.nih.gov/books/NBK395573/
Google Scholar38. Banach, M, Duell, PB, Gotto, AM, et al. Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol 2020; 5: 1124–1135.
Google Scholar | Crossref | Medline39. Bays, HE, Banach, M, Catapano, AL, et al. Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials. J Clin Lipidol 2020; 14: 649–659.e6.
Google Scholar | Crossref | Medline40. Abifadel, M, Varret, M, Rabès, JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154–156.
Google Scholar | Crossref | Medline41. Cohen, J, Pertsemlidis, A, Kotowski, IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37: 161–165.
Google Scholar | Crossref | Medline42. Cohen, JC, Boerwinkle, E, Mosley, TH, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264–1272.
Google Scholar | Crossref | Medline43. Benn, M, Nordestgaard, BG, Grande, P, et al. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010; 55: 2833–2842.
Google Scholar | Crossref | Medline44. Page, MM, Watts, GF. PCSK9 inhibitors – mechanisms of action. Aust Prescr 2016; 39: 164–167.
Google Scholar | Crossref | Medline45. Henry, CA, Lyon, RA, Ling, H. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction. Vasc Health Risk Manag 2016; 12: 163–169.
Google Scholar | Medline46. Stein, EA, Gipe, D, Bergeron, J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012; 380: 29–36.
Google Scholar | Medline47. Raal, F, Scott, R, Somaratne, R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012; 126: 2408–2417.
Google Scholar | Medline48. Sullivan, D, Olsson, AG, Scott, R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308: 2497–2506.
Google Scholar | Crossref | Medline49. Giugliano, RP, Desai, NR, Kohli, P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012; 380: 2007–2017.
Google Scholar | Medline50. Koren, MJ, Scott, R, Kim, JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012; 380: 1995–2006.
Google Scholar | Crossref | Medline51. Stroes, E, Colquhoun, D, Sullivan, D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014; 63: 2541–2548.
Google Scholar | Crossref | Medline52. Koren, MJ, Lundqvist, P, Bolognese, M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014; 63: 2531–2540.
Google Scholar | Crossref | Medline53. Robinson, JG, Nedergaard, BS, Rogers, WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014; 311: 1870–1882.